{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:02:53Z","timestamp":1794261773817,"version":"4.9.0"},"reference-count":23,"publisher":"FapUNIFESP (SciELO)","issue":"suppl 1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>SUMMARY Acute kidney injury is a very common diagnosis, present in up to 60% of critical patients, and its third main cause is drug toxicity. Nephrotoxicity can be defined as any renal injury caused directly or indirectly by medications, with acute renal failure, tubulopathies, and glomerulopathies as common clinical presentations. Some examples of drugs commonly associated with the acute reduction of glomerular filtration rate are anti-inflammatories, antibiotics, such as vancomycin and aminoglycosides, and chemotherapeutic agents, such as cisplatin and methotrexate. Cases of tubulopathy are very common with amphotericin B, polymyxins, and tenofovir, and cases of glomerulopathies are common with VEGF inhibitors, bisphosphonates, and immunotherapy, and it is also common to have more than one clinical presentation related to a single agent. Early diagnosis is essential for the good evolution of the patient, with a reduction of renal exposure to the toxic agent, which requires knowing the risk factors and biomarkers. General measures such as correcting hydroelectrolytic disorders and hypovolemia, monitoring the serum level, avoiding combinations with the synergy of renal injury, and looking for similar options that are less toxic are the foundations for the treatment of complications that are still common and often preventable.<\/jats:p>","DOI":"10.1590\/1806-9282.66.s1.82","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T20:01:36Z","timestamp":1578945696000},"page":"s82-s90","source":"Crossref","is-referenced-by-count":123,"title":["Drug-induced nephrotoxicity"],"prefix":"10.1590","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-2782","authenticated-orcid":false,"given":"Gabriel Teixeira Montezuma","family":"Sales","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9370-0265","authenticated-orcid":false,"given":"Renato Demarchi","family":"Foresto","sequence":"additional","affiliation":[{"name":"Hospital do Rim,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2020]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ccc.2015.06.005","article-title":"Drug-induced acute kidney injury: a focus on risk assessment for prevention","volume":"31","author":"Kane-Gill SL","year":"2015","journal-title":"Crit Care Clin"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2215\/CJN.00150118","article-title":"Pharmacology behind common drug nephrotoxicities","volume":"13","author":"Perazella MA","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/bja\/77.1.82","article-title":"Mechanisms of acute renal failure","volume":"77","author":"Lote CJ","year":"1996","journal-title":"Br J Anaesth"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/FTD.0000000000000589","article-title":"Biomarkers of drug-induced kidney toxicity","volume":"41","author":"Griffin BR","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"1","key":"ref5","first-page":"1","article-title":"Clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Inter Suppl"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12882-017-0536-3","article-title":"The 6R's of drug induced nephrotoxicity","volume":"18","author":"Awdishu L","year":"2017","journal-title":"BMC Nephrol"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2215\/CJN.02050309","article-title":"Renal vulnerability to drug toxicity","volume":"4","author":"Perazella MA","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref8","series-title":"Critical care nephrology","first-page":"214","volume-title":"Drug-induced acute kidney injury","author":"Caires RA","year":"2019","edition":"3rd ed."},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2215\/CJN.14331218","article-title":"Risk of nephrotic syndrome for non-steroidal anti-inflammatory drug users","volume":"14","author":"Bakhriansyah M","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijantimicag.2018.03.024","article-title":"Nephrotoxicity of piperacillin-tazobactam combined with vancomycin: should it be a concern?","volume":"52","author":"Balci C","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/0897190014546114","article-title":"Vancomycin nephrotoxicity: a review","volume":"27","author":"Mergenhagen KA","year":"2014","journal-title":"J Pharm Pract"},{"key":"ref12","article-title":"Manifestations of and risk factors for aminoglycoside nephrotoxicity","author":"Molitoris BA","year":"2017","journal-title":"UpToDate"},{"issue":"6","key":"ref13","first-page":"924","article-title":"Nephrotoxicity of anticancer treatment","volume":"32","author":"Malyszko J","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long-term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha S","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard SC","year":"2016","journal-title":"Oncologist"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella MA","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s12885-015-1536-y","article-title":"Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature","volume":"15","author":"Jia N","year":"2015","journal-title":"BMC Cancer"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1128\/AAC.02634-15","article-title":"Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B.","volume":"60","author":"Rigatto MH","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02319-16","article-title":"Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?","volume":"61","author":"Zavascki AP","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","series-title":"Protocolo cl\u00ednico e diretrizes terap\u00eauticas para manejo da infec\u00e7\u00e3o pelo HIV em adultos","year":"2018"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray AS","year":"2016","journal-title":"Antiviral Res"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1159\/000351648","article-title":"Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence","volume":"37","author":"Issa N","year":"2013","journal-title":"AM J Nephrol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.12688\/f1000research.10192.1","article-title":"Nephrotoxicities","volume":"6","author":"Goldstein SL","year":"2017","journal-title":"F1000Res"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v66s1\/1806-9282-ramb-66-s1-s82.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T04:17:36Z","timestamp":1611375456000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302020001300082&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":23,"journal-issue":{"issue":"suppl 1","published-online":{"date-parts":[[2020]]}},"alternative-id":["S0104-42302020001300082"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.66.s1.82","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}